Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RUNX1: a new beat in the heart of diastolic dysfunction.

Cardiovascular research·2026
Same author

Obesity and Heart Failure With Preserved Ejection Fraction: A Clinical Nexus for Exercise Intolerance.

Obesity (Silver Spring, Md.)·2026
Same author

Multiomics Integration Reveals a Metabolic Myopathy in Cardiometabolic HFpEF.

bioRxiv : the preprint server for biology·2025
Same author

Low Dose GLP-1 Therapy Attenuates Pathological Cardiac and Hepatic Remodelling in HFpEF Independent of Weight Loss.

bioRxiv : the preprint server for biology·2025
Same author

Ultrasound Renal Denervation Attenuates Early Cardiac Remodeling After Acute Myocardial Infarction in a Swine Model of Hypertensions and Dyslipidemia: A Pilot Study.

Clinical and translational science·2025
Same author

Unlocking Mitochondrial Potential: DWORF to the Rescue in Heart Failure.

Circulation research·2025

Related Experiment Video

Updated: Jun 11, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Gene therapy for ischemic heart disease.

Madhav Lavu1, Susheel Gundewar, David J Lefer

  • 1Department of Surgery, Division of Cardiothoracic Surgery and the Carlyle Fraser Heart Center, Emory University School of Medicine, Atlanta, GA 30308, USA.

Journal of Molecular and Cellular Cardiology
|July 6, 2010
PubMed
Summary

Gene therapy offers a promising alternative for ischemic heart disease, improving cardiac function and reducing symptoms. Research focuses on enhancing gene delivery and expression for better patient outcomes.

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

Related Experiment Videos

Last Updated: Jun 11, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

Area of Science:

  • Cardiovascular Research
  • Molecular Medicine
  • Regenerative Medicine

Background:

  • Current treatments for ischemic heart disease (IHD) have limitations, including poor patient compliance, medication side effects, and the need for repeat revascularization procedures.
  • Many patients with IHD remain symptomatic despite maximal medical therapy, highlighting the need for novel therapeutic strategies.
  • Gene therapy presents an attractive alternative for refractory IHD, potentially addressing limitations of conventional treatments.

Purpose of the Study:

  • To review the current state of preclinical and clinical studies on gene therapy for myocardial ischemic disease.
  • To summarize the therapeutic potential of gene therapy in combating IHD.
  • To highlight ongoing research efforts in refining gene therapy techniques for cardiovascular applications.

Main Methods:

  • Review of preclinical studies involving gene therapy with growth factors (VEGF, FGF, HGF) to induce angiogenesis and protect the ischemic heart.
  • Examination of stem cell therapy combined with gene therapy for myogenesis in animal models of myocardial ischemia.
  • Analysis of gene therapy approaches targeting antioxidants, eNOS, HSP, and other anti-apoptotic proteins for cardioprotection.
  • Assessment of safety and efficacy data from human clinical trials of cardiovascular gene therapy.

Main Results:

  • Gene therapy using growth factors has demonstrated angiogenesis induction, apoptosis reduction, and cardioprotection in preclinical models.
  • Combined stem cell and gene therapy shows promise in animal models of myocardial ischemia.
  • Genes encoding antioxidants, eNOS, HSP, and anti-apoptotic proteins have shown significant cardioprotective effects in animal studies.
  • Clinical trials indicate that cardiovascular gene therapy is safe in humans and can lead to symptomatic and objective improvements in cardiac function.

Conclusions:

  • Gene therapy, including growth factor and anti-apoptotic gene delivery, offers significant cardioprotection and potential benefits for ischemic heart disease.
  • Augmenting gene therapy with stem cell therapy is a promising strategy for myocardial regeneration.
  • Ongoing research is focused on improving gene transfection techniques and regulating gene expression in vivo to enhance clinical outcomes for IHD patients.
  • Gene therapy represents a viable and evolving therapeutic avenue for managing ischemic heart disease, particularly in refractory cases.